Corporate News, Acquisitions: Herbalife Ltd, 3D Systems Corporation, Federal National Mortgage Association, Galena Biopharma

 Corporate News, Acquisitions: Herbalife Ltd, 3D Systems Corporation, Federal  National Mortgage Association, Galena Biopharma Inc, Oncomed Pharmaceuticals  PR Newswire  NEW YORK, December 4, 2013  NEW YORK, December 4, 2013 /PRNewswire/ --  Market Buzz Report, provides daily stock updates, highlights notable stock news for Herbalife Ltd.(NYSE:HLF), 3D Systems Corporation(NYSE:DDD), Federal National Mortgage Association(OTCBB:FNMA), Galena Biopharma Inc(NASDAQ:GALE), Oncomed Pharmaceuticals Inc(NASDAQ:OMED).  Herbalife Ltd.(NYSE:HLF) bulls get (more) good news this afternoon as a Belgian appeals court has apparently overturned a previous ruling that found the company was in operation of an pyramid scheme. The company says it has "always believed that the first judgment contained factual errors and was based on misinterpretations of its direct-selling sales method, and was confident that the original judgment would be overturned on appeal."  Free Urgent Insider Catalyst Report ForHLFAvailable Here: http://marketbuzzreport.com/index.php?code=HLF(Or Copy and paste the URL into your browser)  3D Systems Corporation(NYSE:DDD) has unveiled two new printers for its high-end ProJet line: the 4500 and 5500X. The former is called "the first and only continuous-tone, full-color plastic 3D printer available on the market," and the latter is said to print objects featuring "the highest quality, most accurate and toughest multi-material composites." (PRs: I, II)3D adds the 4500 prints semi-rigid plastic parts on a pixel-by-pixel basis in "high-resolution, pantone-like color," and that the 5500X prints twice as fast and produces 60% more volume than rival printers.The 4500 uses 3D's ColorJet Printing platform, and the 5500X its MultiJet Printing platform. Both are the fruits of an R&D budget that has grown rapidly as of late, following criticism 3D hasn't been spending enough on product development. Though its consumer/enthusiast-focused Cube printer line gets more press, the ProJet line still accounts for a much larger portion of 3D's printer sales.  Free Urgent Insider Catalyst Report For DDD Available Here: http://marketbuzzreport.com/index.php?code=DDD(Or Copy and paste the URL into your browser)  "In the long history of bailout deals, no heist of the U.S. taxpayer would approach this one in cynicism and chutzpah," writes Jonathan Laing of Bruce Berkowitz's buyout plan for Federal National Mortgage Association (OTCBB:FNMA) and Freddie (FMCC). One analyst calls it a "three-card monte" scheme in which the preferred holders want taxpayers to pay them off at par, or turn over the keys to the companies wildly valuable operations for little more than a $17B rights offering. Yes, Treasury will have realized $187B in dividends from the GSEs by year end - equal to the amount of the bailout - but that's "merely fair recompense for the enormous risks taxpayers took." Also, more than $80B of the $187B is the write-up of deferred tax assets - it will only be realized if the companies operate profitably for many years, says Laing.  Free Urgent Insider Catalyst Report For FNMA Available Here: http://marketbuzzreport.com/index.php?code=FNMA(Or Copy and paste the URL into your browser)  Shares of Galena Biopharma Inc(NASDAQ:GALE) are trading sharply higher. Perhaps helping to tip sentiment is SA contributor Stock Investor, who is upbeat on NeuVax, calling the outlook for the breast cancer vaccine "tremendous."The author also thinks "the launch of Abstral in the U.S. will help to fund the GALE pipeline and could have the potential to be a large revenue generator."  Free Urgent Insider Catalyst Report For GALE Available Here: http://marketbuzzreport.com/index.php?code=GALE(Or Copy and paste the URL into your browser)  Oncomed Pharmaceuticals Inc(NASDAQ:OMED) announces a development and commercialization agreement with Celgene (CELG). The deal includes demcizumab and "up to six anti-cancer stem cell product candidates."OMED gets $177.25M upfront ($22.25M equity investment).OMED also keeps "global co-development and U.S. co-commercialization rights for five of the six anti-CSC product candidates with 50/50 U.S. profit sharing, and royalties to be received in other territories."CELG has an exclusive option on demcizumab subsequent to which OMED will "co-develop [the drug and] share global development costs on a 1/3 OMED and 2/3 CELG basis."  Free Urgent Insider Catalyst Report ForOMEDAvailable Here: http://marketbuzzreport.com/index.php?code=OMED(Or Copy and paste the URL into your browser)  USMarketBuzz.com is an investment community that Focuses on MicroCap Securities. USMarketBuzz.com is an authorative authentic Google News Site and Leading Provider of Investment Awareness and Featured Company Profiles. If you would like more information regarding our news coverage solutions, please visit http://www.USMarketBuzz.com/  for more details. Get an edge on the market with our Premium News Alerts  that are FREE for a limited time at http://www.USMarketBuzz.com/. Follow us on Facebook: https://www.facebook.com/usmarket.buzz Sign up for our FREE SMS News alerts delivered directly to your mobile phone by texting the word PREPROMO to 27126. (SMS alerts are free, however data rates may apply, check your wireless plan for details.)  DISCLAIMER: FNNewswire (FNNW) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNNW is NOT affiliated in any manner with MarketBuzz Reports, USMarketBuzz.com or any company mentioned herein. The commentary, views and opinions expressed in this release by MarketBuzz Reports and USMarketBuzz.com are solely those of the MarketBuzz Reports & USMarketBuzz.com and are not shared by and do not reflect in any manner the views or opinions of FNNW. The companies that are discussed herein may or may not have approved the statements made in this release. FNNW is not liable for any investment decisions by its readers or subscribers FNNW and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNNW was not compensated by any public company mentioned herein to disseminate this press release.  FNNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.   This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNNW undertakes no obligation to update such statements.  FNNW Contact Information: Company: FN Newswire Contact email: editor@fnnewswire.com U.S. Phone:+1(954)345-0611 SOURCE: FNMedia Group, LLC  SOURCE FN Media Group, LLC  
Press spacebar to pause and continue. Press esc to stop.